After a gruelling decade-long battle, a milestone PBS listing will see this oncology blockbuster made available to thousands of Australians living with certain advanced and metastatic cancers, including rare cancers
PBAC will consider eight submissions with three companies laying the groundwork to secure a broad PBS listing recommendation for their immunotherapies
First-of-its-kind treatment in an area of unmet need scores a Spring PBS listing with the company's GM underlining the importance of innovative medicines for economic growth
It's been quite the week for this company which announced a new General Manager on Friday and from tomorrow, two of its biggest drugs will be expanded
The TGA has approved a new single-pill triple therapy for hypertension as Johnson & Johnson and Dr Falk Pharma expand their franchises
Twelve health sector organisations, including three pharmas, have made the exclusive Best Workplaces in Australia 2026 list. Find out who made the cut
Sandoz ANZ General Manager, Clint Holland, has pulled back the curtain on what makes the biosimilar & generics giant one of Australia’s Best Workplaces
At a gala ceremony in Melbourne last night, the Patients Choice Awards named those making a meaningful difference to the lives of patients
Almost six months after the departure of its Australian General Manager, this company has recruited the leader of a rival pharma as its next Aussie boss
While debate over public funding of weight loss drugs continues, Sigma has reported "above the norm" sales growth driven by GLP-1s as patients load up on other products in store
The head of a boutique law firm specialising in intellectual property relating to life sciences has been tapped as a top IP practitioner globally in two categories
An analysis of the world's top 200 companies reveals three pharmas are raking in seven-figures in net profit in under half an hour. Find out how fast your company makes US$1M
A peak industry body is calling on the Federal Government to freeze the general PBS co-pay price until 2030, naming the Top 5 medicines that have benefited from lower out-of-pocket costs for Australians
From a standing ovation in Chicago to your screen in less than a day, a novel way to learn about the exciting conference sessions that are relevant to Australia
There is a growing divide in Australian pharma between what companies want to pay and what workers are willing to accept with the fallout being felt across industry
A brutal downsizing is coming to pharma with a broad range of roles simply ceasing to exist. Australian experts have revealed the skills and capabilities needed to survive
Dose-limiting toxicities has scuppered an otherwise promising cancer program, seeing a local company cut jobs and scope out possible ways to remain a going concern
After more than a decade with the same company, these executives are moving on. Find out the latest appointments across industry
